Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

222. Cinqair (reslizumab) - To treat severe asthma

Cinqair (reslizumab) - To treat severe asthma Cinqair (reslizumab) U.S. Department of Health and Human Services Search FDA Submit search Cinqair (reslizumab) Cinqair (reslizumab) Company: Teva Respiratory, LLC Application No.: 761033 Approval Date: 03/23/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: May 5, 2016

FDA - Drug Approval Package2016

223. Yoga helps my asthma: Julie’s story and new Cochrane evidence

Yoga helps my asthma: Julie’s story and new Cochrane evidence Yoga helps my asthma: Julie's story and new Cochrane evidence - Evidently Cochrane Search and hit Go By April 27, 2016 // A guest blog from Julie Wood, who has asthma, practices yoga and is the Head of Communication and External Affairs for Cochrane. New Cochrane evidence shows yoga may have benefits for people with asthma I am not at all surprised that the Cochrane evidence out today showed that yoga may be beneficial to those (...) with asthma. I am a devoted yogi who has practised a combination of hot power and bikram yoga about twice a week for the past two years. In my early twenties I decided to take up running and noticed that I could hardly breathe by the end of a run. That started my journey of trying different inhalers in an attempt to control my asthma. I have never had a full on asthma attack, but I have for many years suffered from tightness and wheeziness in my chest that will wake me up at night. This occurs about twice

Evidently Cochrane2016

224. Yoga helps my asthma: Julie’s story and new Cochrane evidence

Yoga helps my asthma: Julie’s story and new Cochrane evidence Yoga helps my asthma: Julie's story and new Cochrane evidence - Evidently Cochrane Search and hit Go By April 27, 2016 // A guest blog from Julie Wood, who has asthma, practices yoga and is the Head of Communication and External Affairs for Cochrane. New Cochrane evidence shows yoga may have benefits for people with asthma I am not at all surprised that the Cochrane evidence out today showed that yoga may be beneficial to those (...) with asthma. I am a devoted yogi who has practised a combination of hot power and bikram yoga about twice a week for the past two years. In my early twenties I decided to take up running and noticed that I could hardly breathe by the end of a run. That started my journey of trying different inhalers in an attempt to control my asthma. I have never had a full on asthma attack, but I have for many years suffered from tightness and wheeziness in my chest that will wake me up at night. This occurs about twice

Evidently Cochrane2016

225. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. 27115376 2016 04 27 2016 05 09 2017 01 30 1538-3598 315 16 2016 Apr 26 JAMA JAMA Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. 1715-25 10.1001/jama.2016.3964 The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM (...) allergy-related asthma. To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitis. Key exclusion criteria were FEV1 less than

JAMA2016

226. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects

Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects 27730194 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects. 00094-2015 The forced oscillation technique (FOT) is gaining clinical acceptance, facilitated by more commercial devices and clinical data (...) . However, the effects of variations in testing protocols used in FOT data acquisition are unknown. We describe the effect of duration of data acquisition on FOT results in subjects with asthma, chronic obstructive pulmonary disease (COPD) and healthy controls. FOT data were acquired from 20 healthy, 22 asthmatic and 18 COPD subjects for 60 s in triplicate. The first 16, 30 and 60 s of each measurement were analysed to obtain total, inspiratory and expiratory resistance of respiratory system ( R rs

ERJ open research2016 Full Text: Link to full Text with Trip Pro

227. Lebrikizumab for severe asthma - second line

Lebrikizumab for severe asthma - second line Lebrikizumab for severe asthma – second line Lebrikizumab for severe asthma – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Lebrikizumab for severe asthma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors (...) ' conclusions Asthma is a long-term condition that affects the lungs and breathing. People with asthma may have coughing, wheezing, chest tightness and breathlessness. Most people can control their symptoms with treatment for most of the time, but some people still have symptoms despite treatment or may suffer from more sudden 'asthma attacks'. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening. Lebrikizumab is a new drug to help people with severe asthma

Health Technology Assessment (HTA) Database.2016

228. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma 26915674 2016 07 04 2016 07 04 1097-6825 138 1 2016 Jul The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. 142-149.e8 10.1016/j.jaci.2015.11.035 S0091-6749(16)00107-X Roflumilast, a selective phosphodiesterase 4 inhibitor (...) , has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists. We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast

EvidenceUpdates2016

229. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial

Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial 26960245 2016 08 07 2017 06 15 2017 06 15 1097-6825 138 2 2016 Aug The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. 441-450.e8 10.1016/j.jaci.2016.01.011 S0091-6749(16)00186-X Results from phase III clinical trials in adults and phase II clinical trials in children (...) and adolescents demonstrate that tiotropium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy. We sought to assess the efficacy and safety of once-daily tiotropium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate symptomatic asthma. In this 48-week, double-blind, placebo-controlled, parallel-group study, 398 patients aged 12 to 17 years were randomized to receive 5 μg (2 puffs of 2.5 μg

EvidenceUpdates2016

230. Factors associated with medication adherence in school-aged children with asthma

Factors associated with medication adherence in school-aged children with asthma 27730181 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Factors associated with medication adherence in school-aged children with asthma. 00087-2015 Adherence to preventive asthma treatment is poor, particularly in children, yet the factors associated with adherence in this age group are not well understood. Adherence was monitored electronically over 6 months in school-aged children who attended (...) a regional emergency department in New Zealand for an asthma exacerbation and were prescribed twice-daily inhaled corticosteroids. Participants completed questionnaires including assessment of family demographics, asthma responsibility and learning style. Multivariable analysis of factors associated with adherence was conducted. 101 children (mean (range) age 8.9 (6-15) years, 51% male) participated. Median (interquartile range) preventer adherence was 30% (17-48%) of prescribed. Four explanatory factors

ERJ open research2016 Full Text: Link to full Text with Trip Pro

231. Adult-onset asthma and periocular xanthogranulomas associated with systemic IgG4-related disease

Adult-onset asthma and periocular xanthogranulomas associated with systemic IgG4-related disease 27152364 2018 11 13 2451-9936 1 2016 Apr American journal of ophthalmology case reports Am J Ophthalmol Case Rep Adult-Onset Asthma and Periocular Xanthogranulomas Associated with Systemic IgG4-Related Disease. 34-37 The aim of this study was to report a case of Adult-Onset Asthma with Periocular Xanthogranulomas (AAPOX) associated with systemic IgG4-related disease (IgG4-RD). A 57-year-old man (...) , Madison, WI; McPherson Eye Research Institute, Madison, WI. Burkat Cat N CN Department of Ophthalmology, The University of Wisconsin, Madison, WI; McPherson Eye Research Institute, Madison, WI. Albert Daniel M DM Department of Ophthalmology, The University of Wisconsin, Madison, WI; McPherson Eye Research Institute, Madison, WI. eng P30 EY016665 EY NEI NIH HHS United States Journal Article United States Am J Ophthalmol Case Rep 101679941 2451-9936 Adult-Onset Asthma IgG4-RD, orbital Periocular

American journal of ophthalmology case reports2016 Full Text: Link to full Text with Trip Pro

232. Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma?

Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma? Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma? - Evidently Cochrane Search and hit Go By March 24, 2016 // A blog for clinicians written by Lynda Ware, giving an overview of four recent Cochrane reviews assessing the effectiveness of LAMAs in asthma care. In the UK 5.4 million people are receiving treatment for asthma. This equates to 1:11 children (...) and 1:12 adults. In 2014 1216 people died from asthma, or, put another way, about 3 people every day. In addition, a patient was hospitalised every 8 minutes as a result of asthma. The cost to the NHS is around £1billion pounds per year. All this is happening despite our greatly improved understanding of the disease and of its treatment. Is there a role for LAMAs in asthma management? Long-acting muscarinic antagonists (LAMAs) are known to be effective in chronic obstructive pulmonary disease

Evidently Cochrane2016

233. Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer.

Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer. Safety of Fluticasone plus Salmeterol in Asthma--Reassuring Data, but No Final Answer. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 26946980 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 12;374(19):1887-8. doi: 10.1056/NEJMe1601040. Epub 2016 Mar 6. Safety of Fluticasone plus Salmeterol in Asthma--Reassuring Data, but No Final Answer. 1 . 1 From the Arizona Respiratory Center, University of Arizona, Tucson. Comment on [N Engl J Med. 2016

NEJM2016

234. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. BACKGROUND: The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS (...) : In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related

NEJM2016

236. Asthma in Children - Diagnosis and Management

Asthma in Children - Diagnosis and Management Asthma in Children - Diagnosis and Management - Province of British Columbia Search default_collection default_frontend MENU theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Health theme_2_collection theme_2_frontend theme_2_collection theme_2_frontend Birth, Adoption, Death, Marriage & Divorce theme_4_collection (...) theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration theme_15_collection theme_15_frontend theme_15_collection theme_15_frontend Family & Social Supports default_collection default_frontend default_collection default_frontend Data Section Navigation Asthma in Children - Diagnosis and Management Effective Date: October 28, 2015 Recommendations and Topics Scope This guideline provides recommendations for the diagnosis and management of asthma in patients aged 1-18 years

Clinical Practice Guidelines and Protocols in British Columbia2016

237. Asthma in Adults - Recognition, Diagnosis and Management

Asthma in Adults - Recognition, Diagnosis and Management Asthma in Adults - Recognition, Diagnosis and Management - Province of British Columbia Search default_collection default_frontend MENU theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Health theme_2_collection theme_2_frontend theme_2_collection theme_2_frontend Birth, Adoption, Death, Marriage & Divorce (...) theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration theme_15_collection theme_15_frontend theme_15_collection theme_15_frontend Family & Social Supports default_collection default_frontend default_collection default_frontend Data Section Navigation Asthma in Adults - Recognition, Diagnosis and Management Effective Date: October 28, 2015 Recommendations and Topics Scope This guideline provides recommendations for the recognition, diagnosis and management of asthma

Clinical Practice Guidelines and Protocols in British Columbia2016

238. Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study

Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study 27730170 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study. 00054-2015 There exists a paucity of data for socially disadvantaged populations describing patterns and predictors of asthma control status and exacerbations during pregnancy (...) , and their relationship to adverse perinatal outcomes. Asthmatic women (n=189) were followed prospectively during pregnancy, with visits at 12, 20, 28 and 36 weeks gestation. Data on loss of control, recurrent uncontrolled asthma and moderate/severe exacerbations were collected at each visit and their relationship to perinatal outcomes examined following stratification for fetal sex. 50% of asthmatic women experienced a loss of control or moderate/severe exacerbation during pregnancy, with 22% of women experiencing

ERJ open research2016 Full Text: Link to full Text with Trip Pro

239. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial.

Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. 26813209 2016 01 27 2016 02 04 2016 10 17 1538-3598 315 4 2016 Jan 26 JAMA JAMA Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. 362-70 10.1001/jama.2015.18589 Asthma and wheezing begin early in life, and prenatal vitamin D deficiency has been (...) variably associated with these disorders in offspring. To determine whether prenatal vitamin D (cholecalciferol) supplementation can prevent asthma or recurrent wheeze in early childhood. The Vitamin D Antenatal Asthma Reduction Trial was a randomized, double-blind, placebo-controlled trial conducted in 3 centers across the United States. Enrollment began in October 2009 and completed follow-up in January 2015. Eight hundred eighty-one pregnant women between the ages of 18 and 39 years at high risk

JAMA2016

240. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.

Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. 26727762 2016 01 05 2016 04 21 2016 05 26 1018-9068 25 5 2015 Journal of investigational allergology & clinical immunology J Investig Allergol Clin Immunol Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. 334-42 (...) Specific allergen immunotherapy is the only treatment modality that might change the natural course of allergic diseases in childhood. We sought to prospectively compare the long-term clinical and immunological effects of sublingual (SLIT) and subcutaneous (SCIT) immunotherapy compared with pharmacotherapy alone. In this single-center, prospective randomized controlled trial, 48 children with mild persistent asthma with/without rhinitis, monosensitized to house dust mites (HDMs) were followed for 3

Journal of investigational allergology & clinical immunology2016